Jan 16, 2019
Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application
Dec 17, 2018
Johnson & Johnson Announces $5 Billion Share Repurchase Program
Dec 04, 2018
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Dec 03, 2018
Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
Dec 03, 2018
IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dec 01, 2018
DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Nov 01, 2018
Investigation Report on China's Infliximab (Johnson & Johnson) Market, 2018-2022
Oct 30, 2018
Johnson & Johnson Innovation Launches Reimagining Respiratory Protection QuickFire Challenge in Collaboration with the U.S. Department of Health and Human Services
Oct 30, 2018
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Oct 26, 2018
Court Issues Ruling in ZYTIGA® Patent Infringement Litigation
Oct 23, 2018
New Phase 2 Data Show Stelara® (Ustekinumab) Sustained Improvement In Disease Activity In Adults With Systemic Lupus Erythematosus Through One Year
Oct 23, 2018
Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.
Sep 19, 2018
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Sep 04, 2018
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
Aug 27, 2018
UPDATE: Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
Aug 20, 2018
Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
Aug 15, 2018
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1
Jul 24, 2018
Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA(TM) (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario
Jul 17, 2018
Janssen Announces U.S. FDA Approval of SYMTUZA(TM) (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Jul 13, 2018
U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application